A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma

Stefano Luminari, Maria Goldaniga, Marina Cesaretti, Lorella Orsucci, Alessandra Tucci, Alessandro Pulsoni, Flavia Salvi, Luca Arcaini, Angelo Michele Carella, Alessandra Tedeschi, Antonello Pinto, Caterina Stelitano, Luca Baldini

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected CRR of 75%. Sixty-nine patients were enrolled; median age was 65 years (45-75), 65% were male, 93% of patients had stage IV disease. Complete and overall response rates were 48% (95% CI = 35.6-60.2) and 86% (CI = 75.0-92.8). The most common grade 3/4 adverse events were neutropenia (43%), thrombocytopenia (7%) and anemia (4%); whereas the rate of febrile neutropenia was very low (3%). At a median follow-up of 22 months (1-43 months), 2-year progression-free survival was 89% (CI = 79-95) and 2-year overall survival was 96% (CI = 87-99). RB combination is active and well tolerated in patients with advanced stage previously untreated INFL.

Original languageEnglish
Pages (from-to)880-887
Number of pages8
JournalLeukemia and Lymphoma
Volume57
Issue number4
DOIs
Publication statusPublished - Apr 2 2016

Fingerprint

Non-Hodgkin's Lymphoma
Febrile Neutropenia
Therapeutics
Neutropenia
Thrombocytopenia
Disease-Free Survival
Anemia
Safety
Survival
Bendamustine Hydrochloride
Rituximab

Keywords

  • Bendamustine
  • chemotherapy
  • indolent non-follicular lymphomas
  • rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. / Luminari, Stefano; Goldaniga, Maria; Cesaretti, Marina; Orsucci, Lorella; Tucci, Alessandra; Pulsoni, Alessandro; Salvi, Flavia; Arcaini, Luca; Carella, Angelo Michele; Tedeschi, Alessandra; Pinto, Antonello; Stelitano, Caterina; Baldini, Luca.

In: Leukemia and Lymphoma, Vol. 57, No. 4, 02.04.2016, p. 880-887.

Research output: Contribution to journalArticle

Luminari, Stefano ; Goldaniga, Maria ; Cesaretti, Marina ; Orsucci, Lorella ; Tucci, Alessandra ; Pulsoni, Alessandro ; Salvi, Flavia ; Arcaini, Luca ; Carella, Angelo Michele ; Tedeschi, Alessandra ; Pinto, Antonello ; Stelitano, Caterina ; Baldini, Luca. / A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. In: Leukemia and Lymphoma. 2016 ; Vol. 57, No. 4. pp. 880-887.
@article{40199d7e90a64559a42f170f73eb1c4e,
title = "A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma",
abstract = "The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected CRR of 75{\%}. Sixty-nine patients were enrolled; median age was 65 years (45-75), 65{\%} were male, 93{\%} of patients had stage IV disease. Complete and overall response rates were 48{\%} (95{\%} CI = 35.6-60.2) and 86{\%} (CI = 75.0-92.8). The most common grade 3/4 adverse events were neutropenia (43{\%}), thrombocytopenia (7{\%}) and anemia (4{\%}); whereas the rate of febrile neutropenia was very low (3{\%}). At a median follow-up of 22 months (1-43 months), 2-year progression-free survival was 89{\%} (CI = 79-95) and 2-year overall survival was 96{\%} (CI = 87-99). RB combination is active and well tolerated in patients with advanced stage previously untreated INFL.",
keywords = "Bendamustine, chemotherapy, indolent non-follicular lymphomas, rituximab",
author = "Stefano Luminari and Maria Goldaniga and Marina Cesaretti and Lorella Orsucci and Alessandra Tucci and Alessandro Pulsoni and Flavia Salvi and Luca Arcaini and Carella, {Angelo Michele} and Alessandra Tedeschi and Antonello Pinto and Caterina Stelitano and Luca Baldini",
year = "2016",
month = "4",
day = "2",
doi = "10.3109/10428194.2015.1091934",
language = "English",
volume = "57",
pages = "880--887",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma

AU - Luminari, Stefano

AU - Goldaniga, Maria

AU - Cesaretti, Marina

AU - Orsucci, Lorella

AU - Tucci, Alessandra

AU - Pulsoni, Alessandro

AU - Salvi, Flavia

AU - Arcaini, Luca

AU - Carella, Angelo Michele

AU - Tedeschi, Alessandra

AU - Pinto, Antonello

AU - Stelitano, Caterina

AU - Baldini, Luca

PY - 2016/4/2

Y1 - 2016/4/2

N2 - The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected CRR of 75%. Sixty-nine patients were enrolled; median age was 65 years (45-75), 65% were male, 93% of patients had stage IV disease. Complete and overall response rates were 48% (95% CI = 35.6-60.2) and 86% (CI = 75.0-92.8). The most common grade 3/4 adverse events were neutropenia (43%), thrombocytopenia (7%) and anemia (4%); whereas the rate of febrile neutropenia was very low (3%). At a median follow-up of 22 months (1-43 months), 2-year progression-free survival was 89% (CI = 79-95) and 2-year overall survival was 96% (CI = 87-99). RB combination is active and well tolerated in patients with advanced stage previously untreated INFL.

AB - The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected CRR of 75%. Sixty-nine patients were enrolled; median age was 65 years (45-75), 65% were male, 93% of patients had stage IV disease. Complete and overall response rates were 48% (95% CI = 35.6-60.2) and 86% (CI = 75.0-92.8). The most common grade 3/4 adverse events were neutropenia (43%), thrombocytopenia (7%) and anemia (4%); whereas the rate of febrile neutropenia was very low (3%). At a median follow-up of 22 months (1-43 months), 2-year progression-free survival was 89% (CI = 79-95) and 2-year overall survival was 96% (CI = 87-99). RB combination is active and well tolerated in patients with advanced stage previously untreated INFL.

KW - Bendamustine

KW - chemotherapy

KW - indolent non-follicular lymphomas

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84961052776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961052776&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1091934

DO - 10.3109/10428194.2015.1091934

M3 - Article

VL - 57

SP - 880

EP - 887

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -